Our observations of clinical specimens demonstrated that total- and phosphorylated-EGFR expression is related to poor outcomes in naïve ALK-rearranged NSCLC patients, indicating that a novel therapeutic strategy is required for these patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.